158 related articles for article (PubMed ID: 18032972)
1. Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment.
Jabbour E; Cortes J; Giles F; Kantarjian H
Cancer J; 2007; 13(6):357-65. PubMed ID: 18032972
[TBL] [Abstract][Full Text] [Related]
2. Current and emerging treatment options in chronic myeloid leukemia.
Jabbour E; Cortes JE; Giles FJ; O'Brien S; Kantarjian HM
Cancer; 2007 Jun; 109(11):2171-81. PubMed ID: 17431887
[TBL] [Abstract][Full Text] [Related]
3. Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.
Giles FJ; DeAngelo DJ; Baccarani M; Deininger M; Guilhot F; Hughes T; Mauro M; Radich J; Ottmann O; Cortes J
Semin Oncol; 2008 Feb; 35(1 Suppl 1):S1-17; quiz S18-20. PubMed ID: 18346528
[TBL] [Abstract][Full Text] [Related]
4. Treatment options in imatinib-resistant chronic myelogenous leukemia.
Marshall HM; Hammond JM
Ann Pharmacother; 2008 Feb; 42(2):259-64. PubMed ID: 18212257
[TBL] [Abstract][Full Text] [Related]
5. Practical management of patients with chronic myeloid leukemia receiving imatinib.
Deininger MW; O'Brien SG; Ford JM; Druker BJ
J Clin Oncol; 2003 Apr; 21(8):1637-47. PubMed ID: 12668652
[TBL] [Abstract][Full Text] [Related]
6. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
Tanaka R; Kimura S
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1387-98. PubMed ID: 18759691
[TBL] [Abstract][Full Text] [Related]
7. [Detection of ABL kinase domain point mutations in chronic myeloid leukemia patients receiving imatinib treatment].
Ouyang Z; DU QF; Liu XL; Zhang S; Zhu HQ; Gong JM; Song LL; Ouyang LY; Liu Z
Nan Fang Yi Ke Da Xue Xue Bao; 2008 May; 28(5):704-6. PubMed ID: 18504184
[TBL] [Abstract][Full Text] [Related]
8. Optimizing therapy of chronic myeloid leukemia.
Deininger MW
Exp Hematol; 2007 Apr; 35(4 Suppl 1):144-54. PubMed ID: 17379100
[TBL] [Abstract][Full Text] [Related]
9. Current status of imatinib as frontline therapy for chronic myeloid leukemia.
Marin D
Semin Hematol; 2010 Oct; 47(4):312-8. PubMed ID: 20875547
[TBL] [Abstract][Full Text] [Related]
10. Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities.
Pawarode A; Sait SN; Nganga A; Coignet LJ; Barcos M; Baer MR
Leuk Res; 2007 Nov; 31(11):1589-92. PubMed ID: 17391756
[TBL] [Abstract][Full Text] [Related]
11. A report of early cytogenetic response to imatinib in two patients with chronic myeloid leukemia at accelerated phase and carrying the e19a2 BCR-ABL transcript.
Li X; Yang J; Chen X; Liu J; Li H; Zheng J; He Y; Chen Z; Huang S
Cancer Genet Cytogenet; 2007 Jul; 176(2):166-8. PubMed ID: 17656262
[TBL] [Abstract][Full Text] [Related]
12. [Circumventing resistance to imatinib therapy in chronic myeloid leukemia].
Minami Y; Naoe T
Gan To Kagaku Ryoho; 2009 Apr; 36(4):544-7. PubMed ID: 19381024
[TBL] [Abstract][Full Text] [Related]
13. Molecular response to imatinib in patient with Ph negative p190 BCR-ABL transcript positive chronic myeloid leukemia with cyclic leukocytosis.
Radojkovic M; Ristic S; Pavlovic S; Colovic M
Leuk Res; 2009 Jun; 33(6):e10-2. PubMed ID: 19091403
[TBL] [Abstract][Full Text] [Related]
14. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
Chien JH; Tang JL; Chen RL; Li CC; Lee CP
Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
[TBL] [Abstract][Full Text] [Related]
15. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
Kim DH; Popradi G; Sriharsha L; Kamel-Reid S; Chang H; Messner HA; Lipton JH
Cancer; 2008 Aug; 113(4):772-81. PubMed ID: 18543309
[TBL] [Abstract][Full Text] [Related]
16. Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia.
Bixby D; Talpaz M
Leukemia; 2011 Jan; 25(1):7-22. PubMed ID: 21102425
[TBL] [Abstract][Full Text] [Related]
17. Has the time come for induction and maintenance imatinib therapy in chronic myeloid leukemia?
Faber E
Leuk Res; 2009 May; 33(5):605-6. PubMed ID: 19062091
[TBL] [Abstract][Full Text] [Related]
18. Imatinib resistance in CML.
Volpe G; Panuzzo C; Ulisciani S; Cilloni D
Cancer Lett; 2009 Feb; 274(1):1-9. PubMed ID: 18653275
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapy in chronic myeloid leukemia.
Jabbour E; Cortes JE; Ghanem H; O'Brien S; Kantarjian HM
Expert Rev Anticancer Ther; 2008 Jan; 8(1):99-110. PubMed ID: 18095887
[TBL] [Abstract][Full Text] [Related]
20. The role of interferon-alpha in the treatment of chronic myeloid leukemia.
Kujawski LA; Talpaz M
Cytokine Growth Factor Rev; 2007; 18(5-6):459-71. PubMed ID: 17703986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
